Clinical trial
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With…
NCT00421733 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00421733 |
|---|---|
| Title | The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors |
| Official title | VITAL Study - Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic… |
| Acronym | VITAL |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetic Nephropathy, Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules, Placebo |
| Enrollment | 281 |
| Start date | Dec 1, 2006 |
| Primary completion | Jun 1, 2009 |
| Completion | Jun 1, 2009 |
| First posted | Jan 12, 2007 |
| Last update posted | Jan 20, 2012 |
| Countries | Germany, Greece, Italy, Netherlands, Poland, Portugal, Puerto Rico, Spain, Taiwan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: